Processing Your Payment
Please do not leave this page until complete. This can take a few moments.
Your search found 63 results
July 21, 2023 -Holliston biotech firm Biostage has rebranded back to its former name, Harvard Apparatus Regenerative Technology.
July 21, 2023 -Holliston biotech firm Biostage has rebranded back to its former name, Harvard Apparatus Regenerative Technology.
-
April 7, 2023 -
Biostage, a cell-therapy biotech company based in Holliston, has received $6 million in commitments from investors to accelerate its clinical development program.
April 7, 2023 -Biostage, a cell-therapy biotech company based in Holliston, has received $6 million in commitments from investors to accelerate its clinical development program.
-
March 28, 2023 -
Holliston biotechnology company Biostage, Inc. has selected Jerry He as its new leader, naming him as CEO and chairman of its board to replace company founder David Green.
March 28, 2023 -Holliston biotechnology company Biostage, Inc. has selected Jerry He as its new leader, naming him as CEO and chairman of its board to replace company founder David Green.
January 12, 2023 -Biostage, Inc. in Holliston has removed the interim designation from David Green’s title and made him biotechnology company’s CEO.
January 12, 2023 -Biostage, Inc. in Holliston has removed the interim designation from David Green’s title and made him biotechnology company’s CEO.
-
August 10, 2022 -
Holliston bioscience company Biostage has hired a public financing and Nasdaq listing expert as its new CFO.
August 10, 2022 -Holliston bioscience company Biostage has hired a public financing and Nasdaq listing expert as its new CFO.
April 13, 2022 -Holliston biotechnology company Biostage Inc. has secured a patent to allow the company known for its esophageal cancer treatment research to pursue treatments for lung cancer.
April 13, 2022 -Holliston biotechnology company Biostage Inc. has secured a patent to allow the company known for its esophageal cancer treatment research to pursue treatments for lung cancer.
- April 6, 2022 -
Holliston biotechnology company Biostage Inc. saw its net losses for the year climb by $3.1 million to approximately $8 million as a result of ongoing wrongful death litigation.
April 6, 2022 -Holliston biotechnology company Biostage Inc. saw its net losses for the year climb by $3.1 million to approximately $8 million as a result of ongoing wrongful death litigation.
November 30, 2021 -Biostage, Inc., a biotech company in Holliston working to bring throat implants to the market, hired its founder and former CEO David Green back to lead the company after roughly six years of absence…
November 30, 2021 -Biostage, Inc., a biotech company in Holliston working to bring throat implants to the market, hired its founder and former CEO David Green back to lead the company after roughly six years of absence…
May 26, 2021 -Holliston biotechnology company Biostage Inc. reported it has $500,000 in operating cash on hand, enough to carry it into the third quarter.
May 26, 2021 -Holliston biotechnology company Biostage Inc. reported it has $500,000 in operating cash on hand, enough to carry it into the third quarter.
-
April 15, 2021 -
Holliston biotechnology company Biostage Inc. cut its yearly losses by $3.4 million through reductions in research & development and administrative expenses.
April 15, 2021 -Holliston biotechnology company Biostage Inc. cut its yearly losses by $3.4 million through reductions in research & development and administrative expenses.
January 21, 2021 -Holliston biotechnology company Biostage, Inc. announced last week it had cut its third quarter losses through reductions in research and development and administrative expenses.
January 21, 2021 -Holliston biotechnology company Biostage, Inc. announced last week it had cut its third quarter losses through reductions in research and development and administrative expenses.
June 15, 2020 -James McGorry resigned as CEO of Holliston biotechnology company Biostage, Inc., officially leaving his position on Feb. 7, according to a company quarterly earnings report released in May.
June 15, 2020 -James McGorry resigned as CEO of Holliston biotechnology company Biostage, Inc., officially leaving his position on Feb. 7, according to a company quarterly earnings report released in May.
-
November 12, 2019 -
The losses rose in the third quarter for Holliston biotech startup Biostage as the company continues to push towards clinical trials of its esophageal implants.
November 12, 2019 -The losses rose in the third quarter for Holliston biotech startup Biostage as the company continues to push towards clinical trials of its esophageal implants.
-
October 30, 2019 -
Biostage has applied to the U.S. Food and Drug Administration for a new esophageal implant, the Holliston bioengineering firm announced Wednesday.
October 30, 2019 -Biostage has applied to the U.S. Food and Drug Administration for a new esophageal implant, the Holliston bioengineering firm announced Wednesday.
-
August 20, 2019 -
Holliston biotech Biostage is on the cusp of an important milestone as it prepares to file an investigational new drug application with the hope of launching clinical trials for an implant intended…
August 20, 2019 -Holliston biotech Biostage is on the cusp of an important milestone as it prepares to file an investigational new drug application with the hope of launching clinical trials for an implant intended…
